The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesChronic neutrophilic leukemia: a clinical perspectiveTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthTreatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasoneSignificant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.Activity of single-agent decitabine in atypical chronic myeloid leukemia.Safety considerations when treating myelofibrosis.Atypical chronic myeloid leukemia in a German Shepherd Dog.Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemiaA case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2aChronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report.Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.The genetic basis of myelodysplasia and its clinical relevanceCSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia.What's different about atypical CML and chronic neutrophilic leukemia?Leukocytosis.Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology.Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions.An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Genomics of chronic neutrophilic leukemia.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.Somatic SETBP1 mutations in myeloid neoplasms.Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia.Enhanced MAPK signaling is essential for CSF3R-induced leukemia.Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report.Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemiaRuxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.
P2860
Q26738514-6ACAF13B-7655-4CF2-96CF-39B12824538AQ26752940-2EA59273-825E-4B91-8CBB-166DB4D0328DQ26781167-0F25B27F-BF9C-4CBB-9D16-42DCBFA88F51Q28828739-D091748E-4AFC-493C-B8F3-282CCC939F59Q33417205-6236B2A9-1C83-4CB6-8873-9F0735B6BAA1Q33417454-FFFAEFB1-4CE9-4A80-A9AF-FC9A50F7EEE8Q33425922-B47275A4-D7C2-44C8-81F0-4BEC8E6C8D2CQ33432285-5BB2538F-280E-447D-A57F-2A836D951053Q33439391-34439DCA-1240-44C1-9212-32541724C8D2Q33591367-302FA35B-6A46-4198-ACD4-1336EA1D508AQ33870649-0B8DE7FC-A7E2-4A2F-9574-7541B8FAC012Q34355272-7B5A4BFB-6B15-4FD8-8B24-0FC146F29C49Q35494379-6DA3FB60-37C5-4B76-A8B5-F8F0E96D81DCQ35944494-82C21EDF-204C-4380-8C8A-3105D4CAD25FQ36291255-A042D862-4997-498B-8DA2-9092BA7C8D64Q36535279-61197FC6-09F5-46FD-921E-A4DE48278843Q36708989-A5BCC1B0-3EE5-404B-80E1-2B542401EEE7Q37046592-0C93B8B0-5BD7-4A48-BC4A-A4D0765D7345Q37349392-B73506ED-E36B-4BA0-BFE7-D67DD96A0C9DQ37390236-56DF4134-EAE9-44B2-9514-14CEDDD67790Q37431993-6B8492A2-1035-4DC2-8B5D-E9E05C7683F3Q37606895-9D235B2E-A917-4140-8778-060644DBCDB6Q38205948-5E0D828C-474B-40F7-8657-E97623725057Q38248429-1D04E782-C01F-4C15-8F6B-56E6CC55DC76Q38292400-88A448D5-6EF6-4549-81D7-58687DA1E0AFQ38526017-6DD4CC2E-C1A6-4745-88C0-F75184AED24AQ38556032-DB60689B-6DB0-4415-A49D-848DCE4889F3Q38963410-5CCD2AD9-FFDC-4EE9-9227-A7771E1B5D39Q38993081-56C4548A-0DA7-401C-AF54-E05CC82B4815Q39048645-0EC46F35-F075-4B84-B211-9C54B81B3527Q39059515-AEDBB35D-C6E0-48ED-9180-7C809FAD0DC1Q39139762-B65165E9-64E4-4031-8F31-8F916E8CC7DBQ39266051-8A061145-B9AD-406F-AF27-50AF1C8828BCQ40261602-06944723-7633-46A5-980B-443178FE496AQ40287451-3C7C0878-1D74-456D-9237-FD24E285505EQ40725420-2264A8A3-BB6B-4516-AE47-90BE22F3D171Q41190362-E8B04AEA-FC43-4C31-95AE-EA1E15289E88Q41615645-EA3DF0CF-B539-4251-A82C-A39BBAC77EDCQ42157464-B81E9132-992C-4D9B-8350-CDE1FE36C53DQ42344556-1DC48F47-A520-4635-9946-3B986F698A9C
P2860
The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The new genetics of chronic ne ...... ns for diagnosis and treatment
@en
The new genetics of chronic ne ...... s for diagnosis and treatment.
@nl
type
label
The new genetics of chronic ne ...... ns for diagnosis and treatment
@en
The new genetics of chronic ne ...... s for diagnosis and treatment.
@nl
prefLabel
The new genetics of chronic ne ...... ns for diagnosis and treatment
@en
The new genetics of chronic ne ...... s for diagnosis and treatment.
@nl
P2860
P1433
P1476
The new genetics of chronic ne ...... ns for diagnosis and treatment
@en
P2093
Jason Gotlib
Julia E Maxson
P2860
P304
P356
10.1182/BLOOD-2013-05-500959
P407
P577
2013-07-29T00:00:00Z